CoChat
Sign Up
Cited by 41

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial

Branch, Kelley R.H., Dagenais, Gilles R., Avezum, Alvaro, Basile, Jan, Conget, Ignacio, Cushman, William C., Jansky, Petr, Lakshmanan, Mark, Lanas, Fernando, Leiter, Lawrence A., Pais, Prem, Pogosova, Nana, Raubenheimer, Peter J., Ryden, Lars, Shaw, Jonathan E., Sheu, Wayne H.H., Temelkova‐Kurktschiev, Theodora, Bethel, M. Angelyn, Gerstein, Hertzel C., Chinthanie, Ramasundarahettige, Probstfield, Jeffrey L.·2022·European Journal of Heart Failure
DOI 10.1002/ejhf.2670
Open this paper in CoChat — free account

Abstract

Aims: People with diabetes are at high risk for cardiovascular events including heart failure (HF). We examined the effect of the glucagon‐like peptide 1 agonist dulaglutide on incident HF events and other cardiovascular outcomes in those with or without prior HF in the randomized placebo‐controlled Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial. Methods and results: The REWIND major adverse cardiovascular event (MACE) outcome was the first occurrence of a composite endpoint of non‐fatal myocardial infarction, non‐fatal stroke, or death from cardiovascular causes (including unknown causes). In this post‐hoc analysis, a HF event was defined as an adjudication‐confirmed hospitalization or urgent evaluation for HF. Of the 9901 participants studied over a median follow‐up of 5.4 years, 213/4949 (4.3%) randomly assigned to dulaglutide and 226/4952 (4.6%) participants assigned to placebo experienced a HF event (hazard ratio [HR] 0.93, 95% confidence interval [CI] 0.77–1.12; p = 0.456). In the 853 (8.6%) participants with HF at baseline, there was no change in either MACE or HF events with dulaglutide as compared to participants without HF ( p = 0.44 and 0.19 for interaction, respectively). Combined cardiovascular death and HF events were marginally reduced with dulaglutide compared to placebo (HR 0.88, 95% CI 0.78–1.00; p = 0.050) but unchanged in patients with and without HF at baseline ( p = 0.31). Conclusions: Dulaglutide was not associated with a reduction in HF events in patients with type 2 diabetes regardless of baseline HF status over 5.4 years of follow‐up.

Overview

Integrity signals

Registry

Crossref · 10.1002/ejhf.2670

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 15

  1. 10.1001/jama.2010.1322 · DOI · Paper page
  2. 10.1161/JAHA.119.014402 · DOI
  3. 10.1056/NEJMoa2108269 · DOI · Paper page
  4. 10.1161/CIRCRESAHA.118.311371 · DOI
  5. 10.2337/dc17-0697 · DOI · Paper page
  6. 10.1016/S0140-6736(18)32261-X · DOI · Paper page
  7. 10.1002/ejhf.1673 · DOI
  8. 10.1016/S0140-6736(19)31149-3 · DOI · Paper page
  9. 10.1111/dom.13028 · DOI
  10. 10.2337/diacare.24.9.1614 · DOI · Paper page
  11. 10.1016/S1262-3636(17)30068-X · DOI
  12. 10.1002/ejhf.657 · DOI · Paper page
  13. 10.1056/NEJMoa1901118 · DOI · Paper page
  14. 10.1056/NEJMoa1612917 · DOI · Paper page
  15. 10.1002/pds.1741 · DOI

Cited by

Sorted by citations

Metadata

Authors
Branch, K. R. H., Dagenais, G. R., Avezum, A., Basile, J., Conget, I., Cushman, W. C., Jansky, P., Lakshmanan, M., Lanas, F., Leiter, L. A., Pais, P., Pogosova, N., Raubenheimer, P. J., Ryden, L., Shaw, J. E., Sheu, W. H. H., Temelkova‐Kurktschiev, T., Bethel, M. A., Gerstein, H. C., Chinthanie, R., & Probstfield, J. L.
Affiliations
  • University of Washington Heart Institute Seattle WA USA
  • Institut Universitaire de Cardiologie et Pneumologie de Québec Université Laval Québec City Québec Canada
  • International Research Center Hospital Alemão Oswaldo Cruz São Paulo Brazil
  • Medical University of South Carolina Ralph H Johnson VA Medical Center Charleston SC USA
  • Endocrinology and Nutrition Department Hospital Clínic i Universitari Barcelona Spain
  • University of Tennessee Health Science Center Memphis TN USA
  • University Hospital Motol Prague Czech Republic
  • Eli Lilly & Co Indianapolis IN USA
  • Universidad de La Fontera Temuco Chile
  • Li Ka Shing Knowledge Institute, St. Michael's Hospital University of Toronto Toronto Ontario Canada
  • St. John's Research Institute Bangalore India
  • National Medical Research Center of Cardiology Moscow Russia
  • Division of Endocrinology University of Cape Town Cape Town South Africa
  • Department of Medicine K2 Karolinska Institute Stockholm Sweden
  • Baker Heart and Diabetes Institute Melbourne Victoria Australia
  • Division of Endocrinology and Metabolism Taipei Veterans General Hospital Taipei Taiwan
  • Robert Koch Medical Center Sofia Bulgaria
  • Population Health Research Institute Hamilton Health Sciences and McMaster University Hamilton Ontario Canada
ORCID
Venue
European Journal of Heart Failure
Publisher
Oxford University Press (OUP)
Published
2022-09-20
Volume
24
Issue
10
Pages
1805-1812
ISSN
  • 1388-9842
  • 1879-0844
DOI
10.1002/ejhf.2670
Cited by
41
References
14
Language
en
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Funders
Eli Lilly and Company

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review